• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

作者信息

Reid I R

机构信息

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

出版信息

Expert Opin Drug Saf. 2022 Dec;21(12):1441-1443. doi: 10.1080/14740338.2022.2160445. Epub 2022 Dec 27.

DOI:10.1080/14740338.2022.2160445
PMID:36538034
Abstract
摘要

相似文献

1
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?接受罗莫索单抗治疗的骨质疏松症患者发生心血管事件的风险是什么？
Expert Opin Drug Saf. 2022 Dec;21(12):1441-1443. doi: 10.1080/14740338.2022.2160445. Epub 2022 Dec 27.
2
Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R.
Expert Opin Drug Saf. 2023 Jan;22(1):103-104. doi: 10.1080/14740338.2023.2173737. Epub 2023 Jan 29.
3
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.罗莫佐单抗治疗女性骨质疏松症：疗效、安全性和心血管风险。
Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577.
4
Amgen and UCB announce increased cardiovascular risk in patients receiving romosozumab, an anti-sclerotin antibody.
Rheumatology (Oxford). 2017 Aug 1;56(8):e21. doi: 10.1093/rheumatology/kex244.
5
Cardiovascular Safety and Sclerostin Inhibition.心血管安全性与硬骨素抑制
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1845-1853. doi: 10.1210/clinem/dgab193.
6
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
7
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.阿仑膦酸钠和罗莫佐单抗试验中心血管事件发生率差异的解释。
Osteoporos Int. 2020 Jun;31(6):1019-1021. doi: 10.1007/s00198-020-05379-z. Epub 2020 Apr 4.
8
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.一项评价罗莫佐单抗治疗男性骨质疏松症的疗效和安全性的 III 期随机安慰剂对照试验。
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193. doi: 10.1210/jc.2017-02163.
9
Bones, heart and the new anabolic agent romosozumab.骨骼、心脏与新型合成代谢药物罗莫佐单抗
Postgrad Med J. 2019 Oct;95(1128):521-523. doi: 10.1136/postgradmedj-2019-136699. Epub 2019 Aug 17.
10
Romosozumab (Evenity) for postmenopausal osteoporosis.罗莫单抗（艾地骨化醇）用于绝经后骨质疏松症。
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86.

引用本文的文献

1
Proteome-Wide Mendelian Randomization Identifies Natriuretic Peptide-B and Novel Proteins as Potential Regulators of Pulse Pressure in Humans.全蛋白质组孟德尔随机化研究确定利钠肽B和新型蛋白质为人类脉压的潜在调节因子。
J Am Heart Assoc. 2025 Aug 19;14(16):e037596. doi: 10.1161/JAHA.124.037596. Epub 2025 Aug 12.
2
Treatment Considerations for Severe Osteoporosis in Older Adults.老年人严重骨质疏松症的治疗考量
Drugs Aging. 2025 May;42(5):395-412. doi: 10.1007/s40266-025-01205-5. Epub 2025 Apr 16.
3
Cardiovascular safety of osteoanabolic agents.
骨合成代谢药物的心血管安全性。
J Bone Miner Metab. 2025 Jan;43(1):26-32. doi: 10.1007/s00774-025-01580-4. Epub 2025 Jan 17.
4
Cardiovascular outcomes of romosozumab treatment-real-world data analysis.罗莫单抗治疗的心血管结局——真实世界数据分析
JBMR Plus. 2024 Dec 10;9(1):ziae146. doi: 10.1093/jbmrpl/ziae146. eCollection 2025 Jan.
5
Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials.罗莫佐单抗的疗效和安全性：安慰剂对照试验的荟萃分析。
J Bone Miner Metab. 2024 Sep;42(5):492-502. doi: 10.1007/s00774-024-01531-5. Epub 2024 Jul 8.
6
Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.地舒单抗与双膦酸盐类药物治疗原发性骨质疏松症的比较：随机对照试验中安全性的荟萃分析。
Osteoporos Int. 2024 Aug;35(8):1377-1393. doi: 10.1007/s00198-024-07118-0. Epub 2024 May 11.